Akeso, Inc. (9926.HK)
- Previous Close
48.450 - Open
48.850 - Bid 48.650 x --
- Ask 48.700 x --
- Day's Range
47.950 - 49.000 - 52 Week Range
30.300 - 55.000 - Volume
3,027,080 - Avg. Volume
4,402,073 - Market Cap (intraday)
42.167B - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
18.59 - EPS (TTM)
2.620 - Earnings Date Mar 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
61.79
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK105, a PD-1 monoclonal antibody to treat classic Hodgkin's lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals; AstraZeneca Pharmaceuticals; Summit Therapeutics Inc.; and Shenzhen Chipscreen Biosciences Co., Ltd. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.
www.akesobio.comRecent News: 9926.HK
Performance Overview: 9926.HK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 9926.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 9926.HK
Valuation Measures
Market Cap
41.95B
Enterprise Value
42.60B
Trailing P/E
18.52
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.29
Price/Book (mrq)
8.27
Enterprise Value/Revenue
9.41
Enterprise Value/EBITDA
20.99
Financial Highlights
Profitability and Income Statement
Profit Margin
44.81%
Return on Assets (ttm)
15.05%
Return on Equity (ttm)
54.97%
Revenue (ttm)
4.53B
Net Income Avi to Common (ttm)
2.03B
Diluted EPS (ttm)
2.620
Balance Sheet and Cash Flow
Total Cash (mrq)
2.39B
Total Debt/Equity (mrq)
66.19%
Levered Free Cash Flow (ttm)
-1.57B
Research Analysis: 9926.HK
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: 9926.HK
9926.HK does not have Company Insights